Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 213-234-5
CAS number: 931-36-2
The oral LD50 was ca 731 mg/kg bw, the inhalation LC50 (after 8 h exposure) was >0.03 mg/L and the dermal LD50 was >400 mg/kg bw.
an acute oral toxicity study, comparable to OECD 401, Wistar rats
(5/sex/dose) were administered 2-ethyl-4-methylimidazole at 464, 681 and
1000 mg/kg bw by single dose (gavage) followed by a 14-day observation
period (1985). Clinical signs included dyspnea, abnormal position,
apathy, staggering, tremors, twitching, convulsion of the jaws, fibr.
contractions, urine intense yellow, piloerection and poor general state.
Findings at necropsy included: general congestive hyperemia (only in
animals that died). The LD50 for males was ca. 754 mg/kg bw. The LD50
for females was ca. 681 mg/kg bw. The LD50 for males/females was ca. 731
another study, comparable to OECD 401, Sprague-Dawley rats (5/sex/dose)
were administered 2-ethyl-4-methylimidazole at at 1000, 4640 and 10000
mg/kg bw by single dose (gavage) followed by a 14-day observation period
(1977). Clinical signs included Dyspnea, apathy, belly-side position,
staggering, tremors, twitching, spastic gait, convulsion of the jaws,
slight hair loss, salivation, poor general condition. Findings at
necropsy included, heart: acute dilatation, acute passive congestion;
glandular stomach diffusely reddened, astringent; intestine: bloody,
diarrhoea-like content. The LD50 was 1000 mg/kg bw.
an acute inhalation toxicity study, comparable to OECD 403, rats
(3/sex-dose) were exposed for 8 hours to a saturated
2-ethyl-4-methylimidazole atmosphere vapour at 20°C (0.03 mg/L) followed
by a 14-day observation period (1977). No mortality occurred. Clinical
signs consisted of distinct mucous membrane irritation and necropsy was
without findings.The LC50 was > 0.03 mg/L.
an acute dermal toxicity study, comparable to OECD 402, Vienna White
Rabbits (5/sex) were administered 2-ethyl-4-methylimidazole (400 mg/kg
bw) (1979). 2-ethyl-4-methylimidazole was dissolved in distilled water
and applied on the skin (skin area of approx 180 cm2) and covered in
aluminium foil fixed with adhesive tape. The treated skin was washed
after 24 hours and a 8 day observation period followed. No mortality was
observed during this period resulting in a LD50 > 400mg/kg bw.
As no mortality
was observed in the acute inhalation toxicity study (LC50 > 0.03 mg/L,
highest possible concentration) and acute dermal study (LD50 > 400 mg/kg
bw), classification for acute inhalation and dermal toxicity is not
needed. Based on the available data,
2-ethyl-4-methylimidazole has to be classified for acute oral toxicity.
According to the EU Classification, Labelling and Packaging of
Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008, the
classification is H302, Cat. 4.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again